Go Pro
→ The retirement stock I'd buy before Nvidia today (From Chaikin Analytics) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
argenex SE stock logo
ARGX
argenex
$1,049.42
+2.9%		$900.50
$661.85
▼
$1,058.69
$65.54B0.46346,189 shs135,831 shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$823.58
-1.2%		$705.74
$541.00
▼
$847.00
$84.64B0.22842,609 shs117,645 shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$214.09
+1.3%		$190.11
$35.64
▼
$220.34
$45.78B1.393.01 million shs1.14 million shs
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$550.20
-0.5%		$496.59
$374.17
▼
$555.69
$139.49B0.31.43 million shs189,972 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
argenex SE stock logo
ARGX
argenex
+0.83%+2.67%+11.03%+24.23%+50.52%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
+0.61%+2.88%+27.07%+32.79%+45.63%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-0.09%-2.14%+11.71%+38.16%+492.60%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
+0.96%+4.67%+15.81%+26.45%+42.14%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
argenex SE stock logo
ARGX
argenex
$1,049.42
+2.9%		$900.50
$661.85
▼
$1,058.69
$65.54B0.46346,189 shs135,831 shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$823.58
-1.2%		$705.74
$541.00
▼
$847.00
$84.64B0.22842,609 shs117,645 shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$214.09
+1.3%		$190.11
$35.64
▼
$220.34
$45.78B1.393.01 million shs1.14 million shs
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$550.20
-0.5%		$496.59
$374.17
▼
$555.69
$139.49B0.31.43 million shs189,972 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
argenex SE stock logo
ARGX
argenex
+0.83%+2.67%+11.03%+24.23%+50.52%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
+0.61%+2.88%+27.07%+32.79%+45.63%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-0.09%-2.14%+11.71%+38.16%+492.60%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
+0.96%+4.67%+15.81%+26.45%+42.14%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
argenex SE stock logo
ARGX
argenex
2.88
Moderate Buy$1,157.5010.30% Upside
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
2.62
Moderate Buy$801.70-2.66% Downside
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
2.95
Moderate Buy$167.89-21.58% Downside
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
2.92
Moderate Buy$563.502.42% Upside

Current Analyst Ratings Breakdown

Latest RVMD, VRTX, REGN, and ARGX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/26/2026
argenex SE stock logo
ARGX
argenex
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$1,350.00 ➝ $1,415.00
8/26/2026
argenex SE stock logo
ARGX
argenex
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeNeutral ➝ Buy$1,400.00
8/24/2026
argenex SE stock logo
ARGX
argenex
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Hold
8/24/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
8/21/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Sanford C. Bernstein logo
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetMarket Perform$151.00 ➝ $179.00
8/18/2026
argenex SE stock logo
ARGX
argenex
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$1,030.00 ➝ $1,095.00
8/18/2026
argenex SE stock logo
ARGX
argenex
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$1,200.00 ➝ $1,230.00
8/18/2026
argenex SE stock logo
ARGX
argenex
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$1,025.00 ➝ $1,100.00
8/18/2026
argenex SE stock logo
ARGX
argenex
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$1,050.00 ➝ $1,150.00
8/18/2026
argenex SE stock logo
ARGX
argenex
Citizens Jmp logo
Citizens Jmp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetMarket Outperform$932.00 ➝ $1,200.00
8/18/2026
argenex SE stock logo
ARGX
argenex
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$940.00 ➝ $1,202.00
(Data available from 8/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
argenex SE stock logo
ARGX
argenex
$4.25B15.45$22.14 per share47.40$134.54 per share7.80
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$14.34B5.91$41.72 per share19.74$308.01 per share2.67
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$11.58M3,962.74N/AN/A$12.16 per share17.61
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$12.00B11.64$17.66 per share31.16$79.78 per share6.90
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
argenex SE stock logo
ARGX
argenex
$1.29B$26.0440.2328.351.0532.19%43.59%36.66%N/A
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$4.50B$40.4620.3216.301.4127.86%13.47%10.34%10/28/2026 (Estimated)
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$1.13B-$8.82N/AN/AN/AN/A-88.20%-57.85%11/4/2026 (Estimated)
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$3.95B$17.1831.9929.712.2735.00%23.09%16.72%11/2/2026 (Estimated)

Latest RVMD, VRTX, REGN, and ARGX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2026Q2 2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$2.04-$3.06-$1.02-$3.06$1.77 millionN/A
8/3/2026Q2 2026
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$4.74$4.73-$0.01$4.31$3.23 billion$3.33 billion
7/30/2026Q2 2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$10.16$14.29+$4.13$12.23$3.82 billion$4.29 billion
7/21/2026Q2 2026
argenex SE stock logo
ARGX
argenex
$5.86$7.32+$1.46$7.32$1.45 billion$1.54 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
argenex SE stock logo
ARGX
argenex
N/AN/AN/AN/AN/A
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$3.760.45%N/A9.29%N/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
N/AN/AN/AN/AN/A
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
N/AN/AN/AN/AN/A

Latest RVMD, VRTX, REGN, and ARGX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/30/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
quarterly$0.940.46%8/18/20268/18/20268/31/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
argenex SE stock logo
ARGX
argenex
N/A
5.12
4.89
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.06
3.34
2.78
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
0.40
11.38
11.38
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
N/A
3.19
2.74

Institutional Ownership

CompanyInstitutional Ownership
argenex SE stock logo
ARGX
argenex
60.32%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
83.31%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
94.34%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
90.96%

Insider Ownership

CompanyInsider Ownership
argenex SE stock logo
ARGX
argenex
2.43%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
6.97%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
7.60%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
0.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
argenex SE stock logo
ARGX
argenex
1,86362.56 million61.04 millionOptionable
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
15,410102.96 million95.78 millionOptionable
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
250214.34 million198.05 millionOptionable
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
6,400253.80 million253.30 millionOptionable

Recent News About These Companies

Vertex Pharmaceuticals Up 15% in a Month: How to Play the Stock
 |  zacks.comhttps://www.zacks.com/stock/news/2980231/vertex-pharmaceuticals-up-15-in-a-month-how-to-play-the-stock?cid=cs-stocknewsapi-ft-analyst_blog|rank_focused-2980231
2 Large-Cap Stocks to Research Further and 1 We Question
 |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/2-large-cap-stocks-research-093113035.html
Vertex Pharmaceuticals Up 15% in a Month: How to Play the Stock
 |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/vertex-pharmaceuticals-15-month-play-133300498.html
Man Group plc Acquires New Stake in Vertex Pharmaceuticals Incorporated $VRTX
August 26 at 6:32 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-man-group-plc-acquires-new-stake-in-vertex-pharmaceuticals-incorporated-vrtx-2026-08-26/
Roberts Glore & Co. Inc. IL Invests $1.59 Million in Vertex Pharmaceuticals Incorporated $VRTX
August 26 at 6:16 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-roberts-glore-co-inc-il-invests-159-million-in-vertex-pharmaceuticals-incorporated-vrtx-2026-08-26/
Jupiter Topco LLC Makes New $625.80 Million Investment in Vertex Pharmaceuticals Incorporated $VRTX
August 26 at 6:15 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-jupiter-topco-llc-makes-new-62580-million-investment-in-vertex-pharmaceuticals-incorporated-vrtx-2026-08-26/
J. Goldman & Co LP Acquires New Shares in Vertex Pharmaceuticals Incorporated $VRTX
August 26 at 6:01 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-j-goldman-co-lp-acquires-new-shares-in-vertex-pharmaceuticals-incorporated-vrtx-2026-08-26/
Hsbc Holdings PLC Invests $335.81 Million in Vertex Pharmaceuticals Incorporated $VRTX
August 26 at 6:00 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-hsbc-holdings-plc-invests-33581-million-in-vertex-pharmaceuticals-incorporated-vrtx-2026-08-26/
Manning & Napier Advisors LLC Buys Shares of 2,064 Vertex Pharmaceuticals Incorporated $VRTX
August 26 at 5:43 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-manning-napier-advisors-llc-buys-shares-of-2064-vertex-pharmaceuticals-incorporated-vrtx-2026-08-26/
1,160,296 Shares in Vertex Pharmaceuticals Incorporated $VRTX Bought by AWM Investment Company Inc.
August 26 at 3:12 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-1160296-shares-in-vertex-pharmaceuticals-incorporated-vrtx-bought-by-awm-investment-company-inc-2026-08-26/
Vertex Pharmaceuticals (NASDAQ:VRTX) Sets New 1-Year High - Still a Buy?
August 25 at 2:39 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-vertex-pharmaceuticals-nasdaq-vrtx-sets-new-1-year-high-still-a-buy-2026-08-25/
Solas Capital Management LLC Takes Position in Vertex Pharmaceuticals Incorporated $VRTX
August 25 at 6:32 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-solas-capital-management-llc-takes-position-in-vertex-pharmaceuticals-incorporated-vrtx-2026-08-25/
Legal & General Group Plc Invests $928.89 Million in Vertex Pharmaceuticals Incorporated $VRTX
August 25 at 6:24 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-legal-general-group-plc-invests-92889-million-in-vertex-pharmaceuticals-incorporated-vrtx-2026-08-25/
The Manufacturers Life Insurance Company Acquires New Stake in Vertex Pharmaceuticals Incorporated $VRTX
August 25 at 6:23 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-the-manufacturers-life-insurance-company-acquires-new-stake-in-vertex-pharmaceuticals-incorporated-vrtx-2026-08-25/
OMERS ADMINISTRATION Corp Takes Position in Vertex Pharmaceuticals Incorporated $VRTX
August 25 at 5:36 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-omers-administration-corp-takes-position-in-vertex-pharmaceuticals-incorporated-vrtx-2026-08-25/
Cibc World Market Inc. Takes $13.72 Million Position in Vertex Pharmaceuticals Incorporated $VRTX
August 25 at 4:09 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-cibc-world-market-inc-takes-1372-million-position-in-vertex-pharmaceuticals-incorporated-vrtx-2026-08-25/
Elevation Point Wealth Partners LLC Buys New Shares in Vertex Pharmaceuticals Incorporated $VRTX
August 25 at 3:52 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-elevation-point-wealth-partners-llc-buys-new-shares-in-vertex-pharmaceuticals-incorporated-vrtx-2026-08-25/
Commerce Bank Invests $3.99 Million in Vertex Pharmaceuticals Incorporated $VRTX
August 25 at 3:52 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-commerce-bank-invests-399-million-in-vertex-pharmaceuticals-incorporated-vrtx-2026-08-25/
Bank of Nova Scotia Buys New Stake in Vertex Pharmaceuticals Incorporated $VRTX
August 25 at 3:20 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-nova-scotia-buys-new-stake-in-vertex-pharmaceuticals-incorporated-vrtx-2026-08-25/
Inflation Is Rising Again. History Says These 2 Stocks Are Among the Smartest Places to Hide
August 24 at 3:08 PM  |  fool.comhttps://www.fool.com/investing/2026/08/24/inflation-is-rising-again-history-says-these-2-sto/
Osmosis Investment Management UK Ltd Acquires Shares of 21,075 Vertex Pharmaceuticals Incorporated $VRTX
August 24 at 6:23 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-osmosis-investment-management-uk-ltd-acquires-shares-of-21075-vertex-pharmaceuticals-incorporated-vrtx-2026-08-24/

New MarketBeat Followers Over Time

Media Sentiment Over Time

argenex stock logo

argenex NASDAQ:ARGX

$1,049.42 +29.93 (+2.94%)
As of 12:11 PM Eastern
This is a fair market value price provided by Massive. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Regeneron Pharmaceuticals stock logo

Regeneron Pharmaceuticals NASDAQ:REGN

$823.58 -9.99 (-1.20%)
As of 12:11 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Revolution Medicines stock logo

Revolution Medicines NASDAQ:RVMD

$214.09 +2.71 (+1.28%)
As of 12:11 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Vertex Pharmaceuticals stock logo

Vertex Pharmaceuticals NASDAQ:VRTX

$550.20 -2.65 (-0.48%)
As of 12:11 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas